Marginal zone lymphoma (MZL) is a rare type of non-Hodgkin lymphoma that arises from B lymphocytes located in the marginal zone of lymphatic follicles. The disease is associated with the accumulation of malignant lymphocytes in the lymph nodes, spleen, and other tissues of the lymphatic system. MZL can manifest itself in several forms, the most common of which is the olymphomatous form, often associated with chronic inflammation or infections such as Helicobacter pylori infection. The disease can manifest itself with a variety of symptoms, including enlarged lymph nodes, fever, night sweats, and weight loss, which requires careful diagnosis and a comprehensive approach to treatment.
History of the disease and interesting historical facts
The history of marginal zone lymphoma spans several decades, beginning with the first descriptions of various forms of lymphoma in the early 20th century. However, it was in the 1980s, thanks to the development of immunohistochemistry and molecular biology, that clinicians began to more accurately differentiate the various subtypes of lymphoma. In 1993, the World Health Organization (WHO) included marginal zone lymphoma in the classification of non-Hodgkin's lymphomas, establishing the basis for further research and treatment of this disease. It is also worth noting that some forms initially appeared as benign diseases, but it soon became clear that they may have malignant potential, which significantly complicates the clinical management of such patients.
Epidemiology
Marginal zone lymphoma is a relatively rare disease: according to current data, it accounts for 6-8% of all cases of non-Hodgkin's lymphoma. The prevalence of this disease varies depending on the region and population, but it is most often detected in people over 50 years of age. Statistics show that in recent decades there has been a slight increase in the incidence, which may be due to improved diagnostic methods and increased life expectancy of patients. Marginal zone lymphoma is more common in men than in women, which also emphasizes the need for further research to determine the etiological factors.
Genetic predisposition to this disease
Studies show that marginal zone lymphoma may be associated with a number of genetic factors. One of the key points is the presence of the chromosomal translocation (11;18)(q21;q21), which has been identified in many patients and is associated with an aggressive course of the disease. Scientific works have also considered the role of other genes, such as BCL2 and MALT1, which can contribute to oncogenesis in lymphoid tissue. Studies show that the presence of these mutations can increase the risk of developing lymphoma and genetic predisposition is considered an important aspect in the study of the disease.
Risk factors for the development of this disease
Research has identified several risk factors that may contribute to the development of marginal zone lymphoma:
- Chronic infections, such as Helicobacter pylori infection, which can cause gastritis and an increased chance of developing lymphoma in the stomach.
- Autoimmune diseases such as Sjogren's disease or serosanguineous arthritis, which may increase the risk of lymphomas.
- Exposure to certain chemicals, including pesticides, as well as radiation, has also been noted in a number of epidemiological studies.
- Age: Most cases occur in patients over 50 years of age.
- Gender: Men are more likely to develop this type of lymphoma than women.
Diagnosis of this disease
Diagnosis of marginal zone lymphoma involves several stages, starting with a clinical examination and ending with specialized tests. The main symptoms of the disease may include:
- Enlargement of the lymph nodes, which can be either local or generalized.
- Night sweats and increased fatigue.
- Weight loss, which is often a sign of a malignant process.
Laboratory studies typically include a complete blood count, lymph node biopsy, and immunohistochemical staining of tumor cells to identify their characteristic markers. Radiologic techniques such as CT or PET may be used to assess the extent of the disease. The differential diagnosis of DMD is important to exclude other types of lymphomas and lymphoid processes due to the similarity of clinical manifestations.
Treatment
General treatment for marginal zone lymphoma depends on the stage of the disease and may include:
- Monitoring of patients with unfavorable tumor shape or small tumor size and no symptoms.
- Chemotherapy as the main treatment in later stages, usually in combination with other drugs.
- Radiation therapy, especially in the case of localized forms of the disease.
- Immunotherapy, which may include the use of monoclonal antibodies.
- Surgical intervention in cases where the limited form can be removed.
Surgical treatment is usually not the primary method, but may be relevant in some cases to remove tumor tissue.
List of medications used to treat this disease
The main drugs used to treat marginal zone lymphoma include:
- Chemotherapeutic drugs: chlorambucil, cyclophosphamide, vincristine, dexamethasone.
- Monoclonal antibodies such as rituximab and obinutuzumab.
- Immunocytotherapy and agents aimed at stimulating the immune response.
- Hormonal therapies when needed depending on the type of lymphoma location.
Disease monitoring
Disease management involves monitoring patients on an ongoing basis to detect relapses and monitor response to treatment. Prognosis depends on the stage of DMD and the patient's overall health, but overall survival is quite high, especially in the early stages. Possible complications may include:
- Development of secondary infectious pathology.
- Side effects of chemotherapy and radiation therapy, including anemia and impaired immunity.
- Risk of lymphoma transformation into more aggressive forms.
Age-related features of the disease
Marginal zone lymphoma is most often diagnosed in patients over 50 years of age, but in rare cases it can also occur in younger patients. The disease in older people can be more aggressive due to concomitant diseases and decreased immune activity. This type of lymphoma is very rare in children and adolescents, but its age dynamics require further study, especially in the context of genetic predisposition.
Questions and Answers
- What is marginal zone lymphoma? Marginal zone lymphoma is a type of non-Hodgkin lymphoma arising from B lymphocytes in the marginal zone of lymphatic follicles with variable clinical manifestations.
- What are the major risk factors for developing marginal zone lymphoma? Major factors include chronic infections such as التهاب, immune system diseases, and harmful chemical exposures.
- How is marginal zone lymphoma diagnosed? Diagnosis includes clinical examination, lymph node biopsy, molecular testing and radiological methods.
- What are the main treatment methods for this disease? Treatment may include observation, chemotherapy, radiation therapy, and immunotherapy depending on the stage of the disease.
- What is the prognosis for patients with marginal zone lymphoma? The prognosis depends on the stage of the disease and the general condition of the patient, but survival in the early stages is high.
